Press Release

Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Analysis by Top Leading Player Forecast Till 2026

The Global Alpha-1 Antitrypsin Deficiency (Aatd) Augmentation Therapy Market has been supported by late FDA endorsement for Prolastin-C. According to a report published by Fortune Business Insights, titled “AATD Augmentation Therapy: Global Analysis, Insights and Forecast, 2019-2026”, the market will be valued at US$ 1959.8 Mn by the end of 2026.

Browse Complete Report [email protected] https://www.fortunebusinessinsights.com/industry-reports/alpha-1-antitrypsin-deficiency-aatd-treatment-market-100189

The estimated rise in market value from its 2017 value of US$ 1115.5 Mn implies that the market will exhibit a CAGR of 5.9% in the foreacast period. Fortune Business Insights expects that factors such as regulatory approvals and improvements in augmentation therapies will drive the market in this period.

KEY PLAYERS COVERED

Some of the major companies that are present in the global alpha-1 antitrypsin deficiency treatment market are Grifols, CSL, Baxter, Kamada, Takeda, Abeona Therapeutics.

Some of the major companies that are present in the Global Alpha-1 Antitrypsin Deficiency Treatment Market are;

  • Grifols S.A.
  • CSL Limited
  • Baxter
  • Kamada Ltd.
  • Takeda Pharmaceutical Company Limited
  • Abeona Therapeutics Inc., and other players.

Grifols SA’s AlfaCare Program Has Had a Positive Impact on the Global Market

In November 2018, Grifols Sa introduced AlfaCare, a therapy program aimed at providing training and counselling to Alpha-1 Antitrypsin Deficiency (Aatd) Augmentation Therapy Market patients diagnosed with AATD. Grifols stated that with AlfaCare, it aims to encourage new habits in patients and help them manage their disease properly. Research studies have proven that a huge percentage of people diagnosed with AATD were unaware about the symptoms, effects, and ways to treat the disorder. AlfaCare was launched to overcome all such shortcomings and improve the quality of patient care, thereby ascertaining reduced fatality rate of AATD. Thus, AlfaCare has transformed AATD augmentation therapies worldwide and is likely to boost the global AATD augmentation therapy market in the forecast period.

Sample PDF Brochure @ https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/alpha-1-antitrypsin-deficiency-aatd-treatment-market-100189

Segmentation:

By Drug Class
  • Alpha-1 proteinase inhibitor
  • Bronchodilators
  • Steroids
  • Antibiotics
By Route of Administration
  • Oral
  • Injection
  • Inhalation
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Stores

North America to Dominate the Global Market

The growth in global alpha-1 antitrypsin deficiency treatment market is being driven by the emerging guideline for the treatment and diagnosis of alpha-1 antitrypsin deficiency treatment, potential pipeline products and rising awareness of alpha-1 antitrypsin deficiency. Furthermore, the rising prevalence of alpha-1 antitrypsin deficiency is expected to boost the global alpha-1 antitrypsin deficiency treatment market in the forecast period.

New Biological Approval for Prolastin C to Enable Growth of Global Market

In September 2017, Grifols received biologics license approval for Alpha-1 Proteinase Inhibitor to add a new liquid formulation to the currently licensed Prolastin C. The inclusion of this liquid may enable the launch of an additional alternative to the existing therapy. Clinical trials and proven efficacy have favored the approval for this product. With the latest addition to its product portfolio, Grifols will increase its stronghold in the global AATD augmentation therapy market. 

More Trending Topics From Fortune Business [email protected]

Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market to Grow at 5.9% CAGR to Reach US$ 1959.8 Mn by 2026

Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market 2019: Global Industry Overview By Size and Industry Segments Poised for Rapid Growth

Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market 2019: Worldwide Trend, Analysis by Top Leading Player and Forecast Till 2026

Tags

Jesus Rust

Jesus is leading the environment column. He is a very renowned environmentalist and has worked in many projects, some of which are based in faraway lands too. He always encourages environment conservation and sometimes keeps small group talks about the concerns. His writing and editing skills act the cheery on the top of the cake.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close